Shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) dropped 3% on Thursday . The stock traded as low as $5.70 and last traded at $5.90, with a volume of 59,908 shares trading hands. The stock had previously closed at $6.08.

DMTX has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Dimension Therapeutics in a report on Wednesday, June 22nd. Jefferies Group initiated coverage on shares of Dimension Therapeutics in a report on Thursday, June 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Zacks Investment Research raised shares of Dimension Therapeutics from a “sell” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Tuesday, May 17th. Canaccord Genuity reaffirmed a “buy” rating on shares of Dimension Therapeutics in a report on Saturday, May 14th. Finally, Chardan Capital set a $10.00 target price on shares of Dimension Therapeutics and gave the company a “hold” rating in a report on Sunday, August 21st. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Dimension Therapeutics has a consensus rating of “Buy” and an average target price of $17.19.

The stock has a 50-day moving average price of $6.76 and a 200 day moving average price of $7.34. The firm’s market cap is $151.93 million.

Dimension Therapeutics (NASDAQ:DMTX) last issued its earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.06. Equities research analysts predict that Dimension Therapeutics Inc. will post ($1.91) EPS for the current year.

In other news, SVP K. Reed Clark sold 5,000 shares of the business’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. Following the completion of the sale, the senior vice president now owns 5,000 shares in the company, valued at approximately $50,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently bought a new stake in Dimension Therapeutics stock. Jennison Associates LLC bought a new position in Dimension Therapeutics Inc. (NASDAQ:DMTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 742,454 shares of the company’s stock, valued at approximately $8,265,000. Jennison Associates LLC owned approximately 2.97% of Dimension Therapeutics at the end of the most recent quarter.

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.